MCL1 and hematopoietic and lymphoid cell neoplasm: Pharmacologic inhibition of MCL-1 has already been presented as a good strategy to improve VEN efficacy in various hematological cancers [22, 49, 50], however, important safety concerns have been recently raised [53].